Doç. Dr.AYLA HARMANCI

  • İlgi Alanları
  • Diabetes mellitus
  • Hipofiz hastalıkları
  • Adrenal hastalıklar
  • Gonadal hastalıklar
  • Osteoporoz
  • Metabolik kemik hastalıkları
  • Metabolik sendrom

Eğitim ve Uzmanlık
1998 - Ankara Üniversitesi Tıp Fakültesi
2004 - Hacettepe Üniversitesi İç Hastalıkları Uzmanlığı
2008 - Hacettepe Üniversitesi Endokrinoloji ve Metabolizma Hastalıkları Uzmanlığı

Deneyim
2013 - 2021 - Özel Koru Hastanesi Endokrinoloji ve Metabolizma Hastalıkları Kliniği
2017 - Endokrinoloji Doçent
2010 - 2011 - Özel Koru Hastanesi Endokrinoloji ve Metabolizma Hastalıkları Kliniği
2008 - 2010 - Şanlıurfa EAH (Devlet Hizmet Yükümlülüğü)
2004 - 2008 - Hacettepe Üniversitesi Endokrinoloji ve Metabolizma Hastalıkları BD
1999 - 2004 - Hacettepe Üniversitesi İç Hastalıkları AD

Uluslararası hakemli dergilerde yayımlanan makaleler


A1.The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. PPAR Res. 2007;2007:49109. doi: 10.1155/2007/49109.

A2. Hospital-acquired pneumonia: challenges and options for diagnosis and treatment. Harmanci A, Harmanci O, Akova M. J Hosp Infect. 2002 Jul;51(3):160-7. doi: 10.1053/jhin.2002.1230. PMID: 12144794 Review.

A3.Effects of L-thyroxine therapy on circulating leptin and adiponectin levels in subclinical hypothyroidism: a prospective study. Yildiz BO, Aksoy DY, Harmanci A, Unluturk U, Cinar N, Isildak M, Usman A, Bayraktar M.Arch Med Res. 2013 May;44(4):317-20. doi: 10.1016/j.arcmed.2013.04.010. Epub 2013 May 15.

A4.Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Cinar N, Harmanci A, Demir B, Yildiz BO. Hum Reprod. 2012 Jun;27(6):1840-5. doi: 10.1093/humrep/des113. Epub 2012 Apr 3.

A5.Molecular diagnosis and clinical characterization of pseudohypoparathyroidism type-Ib in a patient with mild Albright's hereditary osteodystrophy-like features, epileptic seizures, and defective renal handling of uric acid. Unluturk U, Harmanci A, Babaoglu M, Yasar U, Varli K, Bastepe M, Bayraktar M. Am J Med Sci. 2008 Jul;336(1):84-90. doi: 10.1097/MAJ.0b013e31815b218f.

A6.Predictive ability of fasting plasma glucose for a diabetic 2-h postload glucose value in oral glucose tolerance test: spectrum effect. Karakaya J, Aksoy DY, Harmanci A, Karaagaoglu E, Gurlek A. J Diabetes Complications. 2007 Sep-Oct;21(5):300-5. doi: 10.1016/j.jdiacomp.2006.05.001.

A7.Increased circulating soluble P-selectin in polycystic ovary syndrome. Yildiz BO, Bozdag G, Harmanci A, Otegen U, Boynukalin K, Vural Z, Kirazli S, Haznedaroglu IC, Yarali H. Fertil Steril. 2010 May 1;93(7):2311-5. doi: 10.1016/j.fertnstert.2009.01.121. Epub 2009 Mar 3.

A8.Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Cinar N, Kizilarslanoglu MC, Harmanci A, Aksoy DY, Bozdag G, Demir B, Yildiz BO. Hum Reprod. 2011 Dec;26(12):3339-45. doi: 10.1093/humrep/der338. Epub 2011 Oct 7.

A9.Vitamin D status and seasonal changes in plasma concentrations of 25-hydroxyvitamin D in office workers in Ankara, Turkey. Cinar N, Harmanci A, Yildiz BO, Bayraktar M. Eur J Intern Med. 2014 Feb;25(2):197-201. doi: 10.1016/j.ejim.2013.11.004. Epub 2013 Nov 21.

A10.Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state. Harmanci A, Kandemir N, Dagdelen S, Gonc N, Buyukasik Y, Alikasifoglu A, Kirazli S, Ozon A, Gurlek A. J Diabetes Complications. 2006 Jan-Feb;20(1):40-4. doi: 10.1016/j.jdiacomp.2005.05.003.

A11.Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Harmanci A, Cinar N, Bayraktar M, Yildiz BO. Clin Endocrinol (Oxf). 2013 Jan;78(1):120-5. doi: 10.1111/j.1365-2265.2012.04466.x.

A12.Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS.

Yildiz BO, Bozdag G, Otegen U, Harmanci A, Boynukalin K, Vural Z, Kirazli S, Yarali H. Reprod Biomed Online. 2010 Jan;20(1):150-5. doi: 10.1016/j.rbmo.2009.10.016. Epub 2009 Oct 31.

A13.Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome. Cinar N, Harmanci A, Aksoy DY, Aydin K, Yildiz BO. J Ovarian Res. 2012 Dec 7;5(1):42. doi: 10.1186/1757-2215-5-42.

A14.Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapy. Aksoy DY, Cinar N, Harmanci A, Karakaya J, Yildiz BO, Usman A, Bayraktar M. Med Sci Monit. 2013 Mar 22; 19:210-5. doi: 10.12659/MSM.883847.

A15.Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients. Kepez A, Harmanci A, Hazirolan T, Isildak M, Kocabas U, Ates A, Ciftci O, Tokgozoglu L, Gürlek A. Int J Cardiovasc Imaging. 2009 Feb;25(2):187-93. doi: 10.1007/s10554-008-9369-2.

A16.Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Cinar N, Harmanci A, Bayraktar M, Yildiz BO. Clin Endocrinol (Oxf). 2013 Mar;78(3):379-84. doi: 10.1111/j.1365-2265.2012.04415.x.

A17.Comparison of the effect of closed versus open endotracheal suction systems on the development of ventilator-associated pneumonia. Topeli A, Harmanci A, Cetinkaya Y, Akdeniz S, Unal S. J Hosp Infect. 2004 Sep;58(1):14-9. doi: 10.1016/j.jhin.2004.05.005.

A18.Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Unlütürk U, Harmanci A, Yildiz BO, Bayraktar M. Clin Endocrinol (Oxf). 2010 Apr;72(4):469-74. doi: 10.1111/j.1365-2265.2009.03674.x.

A19. The role of hepatitis C virus genotypes in development of autoimmune diseases. Sanver A, Gurlek A, Simsek H, Tatar G. Diabetes Care. 2001 Jun;24(6):1125-6. doi: 10.2337/diacare.24.6.1125.